Non-small Cell Lung Cancer Study US75 (Z-PACT)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00086268

Acronym

ZPACT

Enrollment

250

Registered

2004-07-01

Start date

2004-04-30

Completion date

2007-10-31

Last updated

2017-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Carcinoma

Keywords

lung cancer, ZPACT, US75, Bone Metastases

Brief summary

This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung cancer. This study will measure the effects of this combination on progression of lung cancer, cancer response to treatments, and development of cancer-related bone lesions.

Interventions

DRUGzoledronic acid

DRUGTaxotere

DRUGCarboplatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or Female patients at least of 18 years old * Patients with diagnosed non-small cell lung cancer that cannot be treated by surgery * Women must not be pregnant or attempting to become pregnant * Able and willing to sign informed consent

Exclusion criteria

* Patients with cancer that has spread to the bone * Patients with cancer that has spread to the brain who are receiving treatment * Patients with kidney disease * Patients treated with other investigational drugs

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026